Until recently, the mechanism of action of PD-1/PD-L1 blocking antibodies was considered to base solely on their ability to block the interaction between PD-1 receptor localised on the surface of T-cells and PD-L1 ligand expressed by cancer cells. The gene discussed is PDCD1; the disease is cancer.